QUOTE AND NEWS
StreetInsider.com  Oct 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/La+Jolla+Pharmaceutical+%28LJPC%29+Reports+GCS-100+Shows+Efficacy+in+Phase+2/9939077.html for the full story.
StreetInsider.com  Aug 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/La+Jolla+Pharmaceutical+%28LJPC%29+Enrolls+First+Patient+in+LJPC-501+Phase+12/9779019.html for the full story.
Insurance Journal  Aug 13  Comment 
R-T Specialty Group has named Dina Dryden assistant vice president of RT Binding Authority in the firm’s La Jolla, Calif. Office. Dryden will be responsible for underwriting complex program and non-program risks through pen insurance contracts....
Benzinga  Aug 4  Comment 
Analysts at Jefferies initiated coverage on La Jolla Pharma (NASDAQ: LJPC) with a Buy rating. The target price for La Jolla Pharma is set to $25. La Jolla Pharma's shares closed at $9.40 on Friday. Imperial Capital initiated coverage on shares...
StreetInsider.com  Aug 4  Comment 
Pike Corporation (NYSE: PIKE) 48.4% HIGHER; signed a definitive merger agreement under which investment firm Court Square Capital Partners in partnership with J. Eric Pike, the Company's Chairman and Chief Executive Officer, will acquire the...
StreetInsider.com  Jul 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/La+Jolla+Pharmaceutical+%28LJPC%29+Prices+4.8M+Common+Offering+at+%2410.50Share/9682625.html for the full story.
Benzinga  Jul 22  Comment 
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its...
StreetInsider.com  Jul 15  Comment 
The following is a list of notable articles to help get you through the lunch hour: Microsoft (MSFT) Said Planning Large Workforce Reduction Soon -> Read this! La Jolla Pharma (LJPC) Buy Rating Reiterated at Wedbush -> Read this! eBay's...
FierceBiotech  Jul 15  Comment 
Successfully treating a mouse is not usually enough to get investors excited, but the promise of an effective drug for nonalcoholic steatohepatitis sent La Jolla Pharmaceuticals' shares up as much as 20% on Tuesday despite very early data.
StreetInsider.com  Jul 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/La+Jolla+Pharmaceutical+%28LJPC%29+Reports+Positive+Pre-clinical+data+for+LJPC-1010+/9660318.html for the full story.
Benzinga  Jul 15  Comment 





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki